News
$Kymera Therapeutics (KYMR.US)$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE![]()
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
